Vañó-Galván, Sergio http://orcid.org/0000-0003-2773-7494
Blume-Peytavi, Ulrike http://orcid.org/0000-0003-3528-3752
Farrant, Paul http://orcid.org/0000-0001-9695-0884
Reygagne, Pascal http://orcid.org/0000-0002-6062-2122
Johansson, Erin
Reed, Catherine http://orcid.org/0000-0002-4150-4569
Marwaha, Simran http://orcid.org/0000-0003-0380-0372
Durand, Frederick
Piraccini, Bianca Maria http://orcid.org/0000-0001-6537-9689
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 7 June 2023
Accepted: 9 October 2023
First Online: 27 October 2023
Declarations
:
: Sergio Vañó-Galván is an advisor for Pfizer and Eli Lilly and Company. Ulrike Blume-Peytavi has served on advisory boards and/or is a consultant and/or is a clinical trial investigator for AbbVie, Amryt, Bayer, Boots Healthcare, Cassiopeia, CeraVe, Concert Pharmaceuticals, Dermocosmétique Vichy, Eli Lilly and Company, Galderma, LEO Pharma, Mayne Pharma Neuroderm, Novartis, Pfizer, Pierre Fabre and Sanofi Regeneron. Paul Farrant is a clinical researcher and advisory board member for Pfizer and an advisor for Eli Lilly and Company. Pascal Reygagne has nothing to declare. Erin Johansson, Catherine Reed, and Frederick Durand are employees and shareholders of Eli Lilly and Company. Simran Marwaha is employee of Adelphi Real World. Bianca Maria Piraccini is an advisor for Almirall, Eli Lilly and Company, ISDIN, Pfizer and Vichy.
: The Disease Specific Programme (DSP) fulfils the definition of a market research survey under the European Pharmaceutical Marketing Research Association (EphMRA) Code of Conduct and is therefore conducted to market research guidelines rather than clinical guidelines [CitationRef removed]. Market research surveys are exempt from requiring Institutional Review Board (IRB) approval; however, the Western IRB conducted a methodological review of the Alopecia Areata DSP and provided an exemption. The DSP was conducted in compliance with the International Council for Harmonisation Declaration of Helsinki. Each respondent provided freely given, specific and informed consent to take part in the DSP and for the processing of their personal data. All data provided by physicians and patients were anonymised.